Physician profile
Robert Willard
NPI 1427097427
$3,508.79
in general payments reported to CMS, 2019-2025
29 companies · $797 in 2025
The $797 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $311 · 2021: $519 · 2022: $443 · 2023: $271 · 2024: $707 · 2025: $797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,775.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $608.34 | 2019-2025 | Skyrizi, Rinvoq |
| Mimedx Group, INC. | $598.11 | 2024-2025 | |
| Janssen Biotech, INC. | $496.78 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $197.86 | 2019-2025 | Libtayo |
| Sun Pharmaceutical Industries INC. | $155.68 | 2019-2025 | |
| Genzyme Corporation | $140.01 | 2019-2025 | |
| Ucb, INC. | $139.80 | 2019-2025 | Bimzelx |
| Genentech USA, INC. | $136.07 | 2019-2024 | Erivedge |
| Leo Pharma INC. | $105.14 | 2020-2024 | Adbry |
| Incyte Corporation | $104.49 | 2021-2025 | Opzelura |
| Biofrontera INC. | $89.81 | 2020-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Misonix INC | $87.34 | 2020-2021 | |
| Allergan, INC. | $81.39 | 2019-2022 | |
| Amgen INC. | $74.89 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $60.69 | 2022-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $54.71 | 2022 | |
| Organogenesis INC. | $53.83 | 2021-2025 | Affinity |
| Lilly USA, LLC | $49.62 | 2019-2023 | Taltz, Olumiant |
| Lifenet Health | $44.44 | 2025 | Theragenesis Wound Matrix |
| E.R. Squibb & Sons, L.L.C. | $42.21 | 2024 | Sotyktu |
| Strata Skin Sciences, INC. | $36.10 | 2025 | Xtrac |
| Galderma Laboratories, L.P. | $35.59 | 2019-2020 | |
| Dermavant Sciences, INC. | $24.57 | 2023 | Vtama |
| Conmed Corporation | $20.42 | 2023 | Visiclear |
| Dermira, INC. | $19.55 | 2019 | |
| Progenacare Global, LLC | $13.90 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.22 | 2024 | Spevigo |
| Dusa Pharmaceuticals, INC. | $12.34 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $11.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Willard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.